Davis Polk advised the underwriters as joint global coordinators on the initial public offering and listing on the Main Board of the Stock Exchange of Hong Kong Limited of 3SBio Inc. The gross proceeds from the offering amounted to approximately HK$5.5 billion (US$711.6 million) prior to any exercise of the over-allotment option.     

3SBio is a leading biotechnology company in China. Its two core products, TPIAO and EPIAO, are market leaders in China and are used in the oncology area to treat chemotherapy-induced thrombocytopenia and anemia, respectively. 3SBio ranked second among PRC companies in terms of sales from all biopharmaceuticals in 2013.     

The Davis Polk corporate team included partners Bonnie Y. Chan, Antony Dapiran and Li He, associates Lulu Lin and Vanessa Ho and registered foreign lawyer Xuelin (Steve) Wang. The tax team included partner John D. Paton and associate Nicholas A. Machen. Members of the Davis Polk team are based in the Hong Kong, Beijing and London offices.    

Copy link to share post